US EditionPublished • loading... • Updated
AxoGen: Q4 Earnings Snapshot
- On Feb. 23, 2026 BioMarin announced full-year 2025 results and provided 2026 guidance, with revenues expected to be $3,325 to $3,425 million.
- VOXZOGO's sales surged, driving 17% total revenue growth in 2025, while Enzyme Therapies advanced 9%, supported by PALYNZIQ, and BioMarin expanded VOXZOGO CANOPY with five new indications.
- Full-Year GAAP results show a net loss of $ million, while non-GAAP results reported $47.7 million net income and a 16.5% gross margin for 2025.
- The acquisition of Amicus Therapeutics, expected to close in Q2'26, includes $3.7 billion in financing, and management expects a Non‑GAAP Operating Margin of approximately 40% for 2026, excluding the post-close impact.
- Upcoming regulatory dates include a PALYNZIQ U.S. PDUFA date on February 28, 2026, and other 1H'26 program milestones; the press release contains extensive forward‑looking statements subject to risks, BioMarin said.
Insights by Ground AI
103 Articles
103 Articles
Coverage Details
Total News Sources103
Leaning Left21Leaning Right10Center36Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 31%
C 54%
15%
Factuality
To view factuality data please Upgrade to Premium